INVA-8001 is under clinical development by Invea Therapeutics and currently in Phase I for Primary Biliary Cholangitis (Primary Biliary Cirrhosis). According to GlobalData, Phase I drugs for Primary Biliary Cholangitis (Primary Biliary Cirrhosis) have a 93% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how INVA-8001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

INVA-8001 overview

INVA-8001 is under development for the treatment of ulcerative colitis, mastocytosis, eosinophil associated gastrointestinal disorders such as eosinophilic gastritis, eosinophilic esophagitis primary sclerosing cholangitis and primary biliary cholangitis. It is being developed based on AlphaMeld platform.

Invea Therapeutics overview

Invea Therapeutics (Invea) is a biotechnology company focuses on the discovery of therapeutics for gastrointestinal and hepatobiliary disorders. Invea is headquartered in Guilford, Connecticut,the US.

For a complete picture of INVA-8001’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.